Status:
COMPLETED
COVID-19 Antibody Responses In Cystic Fibrosis
Lead Sponsor:
Erasmus Medical Center
Collaborating Sponsors:
Queen's University, Belfast
Cystic Fibrosis Foundation
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
Brief Summary
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in...
Detailed Description
This is a prospective, longitudinal cohort study in people with Cystic Fibrosis (pwCF) that involves repeated serial sampling of participants. This study design was chosen to provide comprehensive inf...
Eligibility Criteria
Inclusion
- Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity.
Exclusion
- Refusal to give informed consent
- Contraindication to venepuncture.
- Participants already enrolled in a clinical trial are eligible for enrollment in this study. Inclusion in CAR-CF should not preclude enrollment in other observational clinical trial studies or clinical trials of an investigational medicinal product (CTIMP).
Key Trial Info
Start Date :
May 21 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 19 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04904445
Start Date
May 21 2021
End Date
June 19 2024
Last Update
July 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus Medical Center Sophia Children's Hospital
Rotterdam, South Holland, Netherlands, 3015 GD